Ronald Lennox

Ron invests in the biotechnology and molecular diagnostic sectors. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Proteometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly).

He was founding CEO of Proteometrix, Inc. as well as of CGI Pharmaceuticals, Inc. Ron currently serves as the Chairman of the Board of OpGen, Inc. and on the board of BIKAM Pharmaceuticals, Inc.??

Prior to the founding of CHL Medical Partners, Ron was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs.??

Ron graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania.

Ronald Lennox is the General Partner at HarbourVest Partners. With a background in Financial Services, Ronald Lennox has a rich history of leadership and innovation. Ronald Lennox studied unknown unknown @ Wharton School of the University of Pennsylvania. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.